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Objectives The purpose of this study was to determine the occurrence and causes of readmissions after implantation of
axial flow left ventricular assist device (LVAD).
Background Based on the REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive
Heart Failure) study experience, readmissions after LVAD implantation are thought to be frequent.
Methods We retrospectively analyzed admissions to our facility in a cohort of 115 patients implanted between Janu-
ary 2008 and July 2011 with the HeartMate II axial flow LVAD, of whom 42 were bridged to transplant. To
account for repeated events, Andersen-Gill models were used to determine possible predictors.
Results The patients were followed for 1.4  0.9 years. There were 224 readmissions in 83 patients. The overall read-
mission rate was 1.64  1.97 per patient-year of follow-up. The readmission rate for the first 6 months was 2.0
 2.3 and decreased to 1.2  2.1 during subsequent follow-up. Leading causes were bleeding (66 readmissions
in 34 patients), mostly gastrointestinal bleed (51 in 27 patients), cardiac (51 in 36 patients, most for HF or ar-
rhythmia), infections (32 in 25 patients) of which 6 were pump related, and thrombosis (20 in 15 patients) in-
cluding 13 readmissions due to hemolysis. Preoperative variables associated with (fewer) readmissions in a mul-
tivariate model include residence within our hospital-extended referral zone of Minnesota and the neighboring
states (hazard ratio: 0.66; 95% confidence interval: 0.48 to 0.91; p  0.011), hemoglobin (hazard ratio: 0.91,
95% confidence interval: 0.84 to 0.99; p  0.027) and N-terminal pro–B-type natriuretic peptide (hazard ratio:
0.98; 95% confidence interval: 0.96 to 1.0 per 1,000-unit increase, p  0.022). C-statistic for the model: 0.63.
Conclusions Readmission rates after axial flow LVAD implantation decrease during the first 6 months and then stabilize.
The leading causes are bleeding, cardiac (heart failure and arrhythmia), infections, and thrombosis. (J Am Coll
Cardiol 2013;61:153–63) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.041Left ventricular assist device (LVAD) implantation has
been shown to improve short-term (1 year) survival in stage
D heart failure patients (1), and newer devices are providing
improved durability for longer-term support (2). Thus, their
use is increasing, specifically as destination therapy (DT)
(3), and an increasing number of medical centers are
involved in following patients supported with LVADs. The
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experience (1) suggested that readmissions after LVAD
implantation are frequent. The long-term burden of recur-
ring admissions to the implanting hospital in patients with
the contemporarily used axial flow pumps may be of specific
interest to medical centers involved with this approach to
the treatment of end-stage heart failure.
Patients supported in the long term with axial flow
devices generally feel better after device implantation as a
result of improved hemodynamics and end-organ perfusion.
However, caring for these patients may challenge the
clinician with a unique set of medical problems. Previously
described morbidities include gastrointestinal and cerebrovas-
cular bleeding episodes, infections including those of the device
and its driveline, thromboembolism including thrombus for-
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and right ventricular dysfunction.
A comparative analysis of the ma-
jor causes of readmissions after
LVAD implantation may there-
fore be useful in providing per-
spective and categorizing the rela-
tive importance of morbidity
associated with ongoing LVAD
support.
The aim of this study was to
determine the occurrence, causes,
trends over time, and possible predictors of readmissions to
the implanting hospital after LVAD implantation.
Methods
Patients. All patients surviving to discharge after implan-
tation of a HeartMate II (Thoratec Corporation, Pleasanton
California) LVAD at our institution between January 2008
and July 2011 were screened for readmissions.
We conducted a retrospective analysis of readmissions to
our facility based on chart review. Baseline and follow-up
characteristics of patients were retrieved from the electronic
chart. The glomerular filtration rate was calculated based on
the Modification of Diet in Renal Disease equation. Due to
a general improvement during optimization before the
operation, we differentiated baseline values (at the time of
admission) from preoperative values (the morning before
operation). Patients were censored for death, transplanta-
tion, or last follow-up. The study was approved by the Mayo
Clinic institutional review board.
Evaluation and follow-up for LVAD patients at our
facility includes comprehensive laboratory testing, cardio-
pulmonary exercise test and the 6-min walk test (for patients
who can perform it), imaging (chest x-ray, abdominal
ultrasound, carotid ultrasound, computed tomography when
needed), electrocardiogram, echocardiogram as previously
described (4), hemodynamic right heart catheterization and
coronary angiography, renal function evaluation including
iothalamate clearance, pulmonary function testing, fecal
hemoglobin, and colonoscopy (unless performed within the
previous 10 years). Specialty evaluation is also performed
including assessment for the need for social services, reha-
bilitation, and palliative care. The data obtained on pro-
spective candidates is then carefully reviewed and selection
performed in a multidisciplinary conference. Preoperatively,
patients are usually hospitalized for right heart catheteriza-
tion, inotropic support, and intra-aortic balloon pump as
needed.
Follow-up for LVAD recipients includes pre-scheduled
outpatient visits and telephone follow-up. Visits are sched-
uled monthly for the first 3 months, every 3 months until 1
year, every 4 months in the second year, and every 6 months
in the third and fourth years after implantation. Telephone
Abbreviations
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CI  confidence interval
DT  destination therapy
HR  hazard ratio
LVAD  left ventricular
assist device
NT-proBNP  N-terminal
pro–B-type natriuretic
peptideassistance is available 24/7 by an LVAD coordinator for any ipatient-related questions or concerns with occasional
coordinator-initiated follow-up calls. If a patient requires
hospitalization, our usual preference is to recommend hos-
pitalization at our facility. If the patient’s medical situation
does not allow that, we then recommend stabilization at a
local medical facility with subsequent transfer. On arrival,
patients are hospitalized, appropriate treatment initiated,
and followed by the dedicated multidisciplinary LVAD
service.
LVAD patients are treated with aspirin and warfarin with
a goal international normalized ratio of 1.5 to 2.5, a proton
pump inhibitor, and iron supplementation. If a major
bleeding episode occurs, all anticoagulation is withheld for a
month and then gradually resumed. An effort is made to
identify the possible bleeding source (including upper and
lower endoscopy, extended balloon endoscopy, and capsule
enteroscopy in the case of gastrointestinal bleeding) and to
treat it locally if possible. Lactate dehydrogenase is mea-
sured routinely during follow-up visits and an acute in-
crease, when accompanied by symptoms, may prompt
further evaluation for hemolysis due to pump thrombosis.
Prophylactic antibiotic treatment is given before LVAD
implantation and until 48 h after the operation. We do
not use routine antibiotic prophylaxis thereafter unless
otherwise indicated for endocarditis prophylaxis. Patients
are instructed to meticulously clean the drive-line exit site
daily.
Readmissions. We recorded all readmissions to our treat-
ment facility until January 31, 2012. The date of admission,
duration of stay, and primary reason for readmission was
recorded. Primary diagnosis on discharge note was used to
identify the cause for readmission. Causes were grouped
based on mechanism into major groups including cardiac
causes (arrhythmia, heart failure, chest pain), bleeding (any
bleeding, anemia), infections (ventricular assist device–
related and unrelated infections), thrombotic causes (throm-
boembolism, suspected LVAD thrombosis), LVAD related
(abnormal readouts or alarms), biliary related (biliary colic,
cholecystitis, biliary surgery, ductal cancer), elective read-
missions (mostly for procedures), and other miscellaneous
causes. Major neurological events were recorded as either
thrombotic or bleeding events based on the presentation.
Due to the morbidity related to such events, they are also
reported separately in the results.
Rate calculation. Rate calculations were corrected for
number of patients available and follow-up time normalized
to derive yearly rates. We used the term readmission rate
using readmission per patient-year units. The same was
performed for length of stay to yield the term readmission
duration rate using days per patient-year units. Monthly
grouping (first 6 months) and 3-month grouping for later
follow-up were performed.
Statistical analysis. Descriptive analysis was performed by
presenting the mean  SD for numerical data unless
arkedly non-normal, in which case the median and
nterquartile range (25th and 75th percentiles) were used
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readmission rate where, despite an abnormal distribution,
we thought that the mean value would make better clinical
sense. Assessment of normality for numerical variables was
performed using the Shapiro-Wilks method. Comparison
of readmission rates during different follow-up intervals was
performed using the paired Wilcoxon rank test.
To account for repeated events, analysis for possible
predictors of readmissions was performed using Andersen-
Gill models (5). For parameters evaluated after discharge
from the implantation hospitalization (1-month follow-up),
we evaluated the predictive value affiliated with readmis-
sions occurring after measurement (later than 1 month). For
the multivariate analysis, only parameters with fewer than
20% missing values were used. The multivariable model
considered marginally significant univariate variables (p 
0.10) with model selection using stepwise combined selec-
tion. For each step in the model-fitting process, we included
all records with complete data for the particular terms being
fit.
All p values were 2 sided, and p values 0.05 were
considered to indicate statistical significance. All data were
analyzed with the JMP System software version 8.0 (SAS
Institute, Inc., Cary, North Carolina) and SAS version 9.2
(SAS Institute Inc.).
Results
A total of 137 adult patients underwent implantation with a
permanent continuous flow LVAD. Of these, 13 patients
did not survive to be discharged and 9 were implanted with
pumps other than the HeartMate II (6 Venrassist, 1HM
XVE, 1 HeartWare, 1 Duraheart) and were excluded,
leaving 115 patients for analysis. Patient characteristics are
shown in Table 1. The median age was 62 years, 83% were
male, and 49% had an ischemic etiology for heart failure.
Only 36% were bridged to transplantation. Our patient
group included 11 patients who underwent implantation
with an LVAD for heart failure with predominantly restric-
tive physiology; however, most patients had dilated left
ventricles with reduced ejection fraction.
Patients were followed for 1.4  0.9 years. During this
time, 224 readmissions to our facility were recorded in 83 of
115 patients. Thirty-two patients (28%) were not readmit-
ted, 33 (29%) had 1 readmission, 17 (15%) had 2, and 33
(29%) had 2 readmissions during their follow-up. In the
first month, 25 of 115 patients (22%) and at 1 year, 75
patients (65%) were readmitted. Characteristics of patients
who were readmitted and those who were not are also
shown in Table 1. Patients who were not readmitted were
followed for a shorter duration than those who were
readmitted. They also tended to be younger, with a non-
ischemic etiology and more frequently underwent implan-
tation as a bridge to transplantation.
The rate of readmissions to our facility for the whole
cohort by time after implantation is shown in Figure 1. Dueto the small number of patients with longer follow-up, we
show only the results up to 3 years. Overall, the mean SD
readmission rate was 1.64  1.97, and the median (IQR)
was 1.1 (0 to 2.4) per patient-year of follow-up. The rate
decreased during the first 6 months from 2.6 to 0.9
readmissions per patient-year and remained stable thereaf-
ter. The mean  SD readmission rate for the first 6 months
was 2.0  2.3, and the median (IQR) rate was 2 (0 to 4),
and for the subsequent duration of follow-up, it was 1.2 
2.1 (mean  SD), and the median (IQR) rate was 0.4 (0 to
1.7) per patient-year. The difference between rates during
the 2 follow-up periods was statistically significant (p 
0.0006). The cumulative readmission duration rate by time
after implantation is shown in Figure 2. Trends were similar
to those of the readmission rate, again with a decrease
during the first 6 months after surgery and stabilization
thereafter. The mean  SD readmission duration rate
during the first 6 months was 19.5  39, and the median
(IQR) rate was 4 (0 to 10) (and for the subsequent
follow-up, the mean  SD rate was 7.4  13 and the
median (IQR) rate was 0 (0 to 10) days per patient-year
(p  0.0017 for the difference between intervals). Table 2
shows the readmission rates in patients who underwent
implantation as a bridge to transplantation versus DT.
Overall DT patients had significantly longer follow-up
leading to more readmissions; however readmission rates
were not significantly different between the groups.
Causes of readmission. The readmission rate by cause of
readmission for various time intervals after LVAD implan-
tation is shown in Figure 3. The major causes of readmis-
sion in the first 6 months include bleeding and cardiac-
related causes. These decrease during the second 6 months
of follow-up (together with the miscellaneous causes),
accounting for an overall decrease in readmissions. During
the second year, there was an increased rate of readmissions
for bleeding and fewer cardiac readmissions compared with
the previous interval. During the third year, there were more
cardiac admissions and fewer related to bleeding with an
increase in the rate of thrombosis and of hospitalizations for
elective procedures.
Because the relative burden of readmission may be
influenced by both the rate of readmission and the duration
of stay during readmission, we compared the proportional
impact of the different causes on these 2 variables (Fig. 4).
Bleeding and cardiac causes accounted for more readmis-
sions but accounted for fewer days spent in the hospital
compared with thrombotic and infectious causes. Taken
together the 4 leading causes, accounting for the majority of
readmissions (75%) were bleeding, cardiac, infection, and
thrombosis.
Isolated causes of readmission. The proportion of pa-
tients presenting with a defined cause for readmission is
shown in Figure 5. Although the analysis is limited
because some events were treated in other facilities and
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Characteristic (%)
All Patients
(N 115)
Any Readmission
(n  83)
No Readmissions
(n  32)
Anderson-Gill
p Value
Follow-up, yrs 1.4 0.9 1.5 0.9 0.9 0.5
Demographic
Age, yrs 62 (53–69) 65 (59–70) 54 (38–62) 0.093
Male 96 (83) 71 (85) 25 (78) 0.635
Residence in Minnesota 42 (36) 32 (38) 10 (31) 0.033*
Residence in Minnesota or neighboring state 80 (70) 61 (73) 19 (59) 0.002*
Hypertension 44 (38) 39 (47) 5 (16) 0.088
Diabetes 39 (34) 31 (37) 8 (25) 0.247
Ischemia etiology 56 (49) 48 (57) 8 (25) 0.835
Restrictive etiology 11 (10) 7 (8) 4 (12) 0.459
Bridge to transplantation 42 (36) 24 (29) 18 (56) 0.559
Clinical pre-operatively
Weight, kg 88 18 87 18 90 18 0.746
Systolic blood pressure, mm Hg 101 13 101 13 101 12 0.118
Heart rate, beats/min 77 15 75 14 84 18 0.066
Atrial fibrillation 40 (35) 31 (37) 9 (28) 0.572
NYHA functional class IV 78 (68) 50 (60) 28 (87) 0.199
Previous sternotomy 51 (44) 46 (55) 5 (15) 0.303
Preoperative IABP 47 (41) 28 (34) 19 (59) 0.526
Need for inotrope 74 (65) 52 (63) 22 (69) 0.775
ACEI or ARB 74 (64) 51 (61) 23 (72) 0.770
Beta-blocker 99 (86) 72 (87) 27 (84) 0.503
Loop diuretic 107 (94) 75 (91) 32 (100) 0.604
GFR on admission, ml/min/1.73 m2 55 20 53 21 59 19 0.205
GFR preoperatively, ml/min/1.73 m2 67 24 64 24 76 22 0.008*
Hemoglobin, g% 11.8 1.8 11.7 1.8 12.0 1.8 0.003*
Platelet, 1,000 U 175 75 188 75 141 67 0.306
Bilirubin, mg/dl 1.1 (0.8–1.7) 1 (0.7–1.7) 1.3 (0.9–1.8) 0.177
AST, U/l 34 (25–49) 35 (25–49) 30 (25–51) 0.173
ALT, U/l (n  111) 30 (18–41) 29 (18–39) 30 (17–52) 0.036*
LDH, U/l (n  92) 252 (207–335) 248 (207–328) 262 (198–352) 0.027*
NT-proBNP, 1,000, pg/ml (n  88) 4.4 (2.6–8.3) 4.3 (2.4–8.3) 4.7 (3.0–8.1) 0.022*
Albumin, g% (n  110) 3.8 0.5 3.8 0.5 3.7 0.6 0.940
BUN, mg/dl 26 (18–40) 29 (20–41) 21 (14–31) 0.670
Leitz-Miller score 10  5.6 9 5 12 5 0.585
6-min walk test, m (n  41) 316 110 318 110 308 117 0.393
VO2max (n  53) 10.2 2.9 10.2 2.9 10.1 3.1 0.086
Preoperative echocardiography
Left ventricular diastolic diameter, mm 69 10 68 9 69 11 0.089
Ejection fraction, % 17 (15–21) 17 (15–22) 17 (14–20) 0.399
LA volume index, ml/m2 (n  95) 61 (50–77) 61 (50–77) 61 (48–76) 0.032*
RIMP (n  80) 0.58 0.24 0.56 0.22 0.63 0.30 0.004*
Preoperative catheterization (n  107)
Mean RA pressure, mm Hg 16 7 15 6 16 7 0.653
Mean pulmonary pressure, mm Hg 37 9 37 9 35 11 0.680
RVSWI, g/m2/beat 7.2 3.9 7.8 3.8 5.7 3.7 0.227
Mean wedge pressure, mm Hg 24 8 24 7 25 9 0.129
RA/wedge pressure 0.68 0.28 0.68 0.28 0.68 0.25 0.032*
Cardiac index, l/min/m2 1.9 0.5 2.0 0.5 1.8 0.6 0.166
Operation and postoperatively
Bypass time, min 99 (81–135) 99 (81–126) 97 (81–149) 0.315
Inotropic support duration, h 113 (66–160) 114 (72–144) 96 (48–210) 0.206
Discharged with phosphodiesterase 5 inhibitors 26 (23) 13 (16) 13 (41) 0.272
Duration of hospitalization, days 16 (11–24) 17 (11–24) 14 (10–27) 0.115Continued on the next page
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on the readmissions to the implanting hospital. Approxi-
mately one third of the patients were readmitted due to a
cardiac event. Of these, 18 (51%) underwent implanta-
tion for ischemic etiology. Their preoperative estimates
of right ventricular function were similar to those of the
total group (right index of myocardial performance,
0.55  0.21; right atrial pressure, 16.3  6.6; and right
ventricular stroke work index, 8.5  4.5). One third of
the patients were readmitted due to bleeding. Most
ContinuedTable 1 Continued
Characteristic (%)
All Patients
(N 115)
1-month follow-up
Hemoglobin, g% 10.6 1.6
Sodium, mmol/l 137 3
Platelets, 1,000 U 261 93
INR 1.8 (1.4–2.3)
Albumin, g% (n  92) 3.6 0.5
GFR, ml/min/1.73 m2, (n  108) 83 31
Pump speed, rpm (n  87) 9,400 (9,200–9,600
Pump flow, l/min (n  81) 5.5 0.9
Pump PI (n  84) 5.0 0.7
LVEDD, mm (n  111) 56 11
LVEDD (preoperatively to 1 month), mm 12.6 8.6
Closed aortic valve on echocardiography (n  113) 76 (67)
Values are n (%), mean  SD, or median (interquartile range). Shown are the baseline and 1-mo
implantation (all patients) as well as for the subgroups of patients who had any or no readmissio
association of the various parameters with readmissions using Anderson-Gill model are presented
ACEI angiotensin-converting enzyme inhibitor; ALT alanine aminotransferase; ARB angiot
ltration rate; IABP  intra-aortic balloon pump; INR  international normalized ratio; LA  lef
-terminal pro–B-type natriuretic peptide; NYHA New York Heart Association; PI pulsatility inde
ndex.
Figure 1 Readmission Rate by Time From Implantation
The readmission rate as readmissions per patient-year with time after left ventricubleeding events were gastrointestinal (n  51), 5 were
cerebral, 2 hematuria, 2 uterine, 2 epistaxis, 2 for anemia
of unknown cause, and the rest due to hemoptysis,
hemothorax, and a hematoma (1 each). Bleeding tended
to recur despite our policy to stop anticoagulation.
Within 3 months of the index bleeding event, 3 patients
had 3 subsequent thrombotic episodes and 8 patients had
13 subsequent bleeding episodes. For the duration of
follow-up, 5 patients had 5 subsequent thrombotic epi-
sodes and 12 patients had 24 subsequent bleeding epi-
Any Readmission
(n  83)
No Readmissions
(n  32)
Anderson-Gill
p Value
10.5 1.5 11.0 1.8 0.155
137 3 137 3 0.856
266 100 249 75 0.123
1.8 (1.4–2.4) 1.9 (1.5–2.2) 0.062
3.6 0.6 3.8 0.4 0.108
82 31 85 33 0.395
9,400 (9,200–9,600) 9,400 (9,200–9,600) 0.539
5.5 0.9 5.4 0.8 0.237
4.9 0.7 5.3 0.7 0.803
55 10 59 12 0.091
13.5 8.6 10.4 8.4 0.858
52 (64) 24 (75) 0.006*
low-up characteristics for the cohort of patients discharged after left ventricular assistive device
he implanting facility. N is presented for variables with missing data. p Values for the univariate
istically significant associations (p  0.05).
ceptor blocker; AST aspartate aminotransferase; BUN blood urea nitrogen; GFR glomerular
; LDH  lactate dehydrogenase; LVEDD  left ventricular end-diastolic diameter; NT-proBNP 
right atrial; RIMP right index of myocardial performance; RVSWI right ventricular stroke work
istive device implantation. Spline fit is depicted.)
nth fol
ns to t
. *Stat
ensin re
t atriallar ass
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occurred in 22% and thrombosis in 14%. A detailed
description of the major causes of specific readmissions is
shown in Table 3, specifying the numbers and propor-
tions among DT and bridge to transplantation patients.
Possible predictors for readmissions. A univariate anal-
ysis of the association with readmissions after LVAD
implantation using the Anderson-Gill model was per-
formed for all variables presented in Table 1; p values are
included in the table. Significantly associated variables
are presented in Table 4.
Variables significantly associated with (fewer) readmis-
sions in a multivariate model included residence within our
Figure 2 Readmission Duration Rate by Time From Implantatio
The readmission duration rate is shown as days in readmissions per patient-year
Comparison of Patients With LVAD Implanted as aBridge to Transplanta ion or as Destination TherapyTable 2 Comparison of P tient With LVAD Implanted as aBridge to Transplantation or as Destination Therapy
Variable
BTT
(n  42, 36%)
DT
(n  73, 64%) p Value
No. of readmissions 60 164
Follow-up, yrs 1.1 0.8 1.5 0.9 0.002*
Readmission rate,
per patient-year
0.7 (0–2.4) 1.1 (0.4–2.3) 0.215
Readmission rate during
first 6 months,
per patient-year
0 (0–2.1) 2 (0–4) 0.153
Readmission duration
rate, days per patient-
year
2.8 (0–14.8) 8.1 (1.4–16.5) 0.054
Readmission duration rate
in first 6 months, days
per patient-year
1 (0–18.2) 6.1 (0–-30.4) 0.176
Values are mean  SD or median (interquartile range). *Statistically significant association (p 
0.05).BTT bridge to transplantation; DT destination therapy; IQR interquartile range; LVAD left
entricular assistive device.hospital extended referral zone of Minnesota (MN) and the
neighboring states (MN: 1 for yes, 0 for no) (beta 0.45,
hazard ratio [HR]: 0.64; 95% confidence interval [CI]: 0.48
to 0.85; p  0.002), pre-operative hemoglobin (beta 
0.113; HR: 0.89; 95% CI: 0.83 to 0.96; p  0.004),
preoperative N-terminal pro–B-type natriuretic peptide
(NT-proBNP) per 1,000 U (beta  0.0198; HR: 0.98;
95% CI: 0.96 to 1.0; p  0.044), and closed aortic valve
observed on echocardiography in the first month [aortic
valve: 1 for closed, 0 for no] (beta  0.74; HR: 0.48;95%
CI: 0.34 to 0.67; p 0.001). The C-statistic for the model
was 0.632. The proportional hazards term of the
Anderson-Gill model is exp(3.17  0.45  MN – 0.113 
hemoglobin  0.0198  NT-proBNP – 0.74  aortic
valve) and can be multiplied by the average readmission
rate to yield patient-specific hazard. To account for
possible selection of a sicker population with preserved
ejection fraction (causing aortic valve opening), we per-
formed a second analysis excluding patients with an
ejection fraction at baseline 25%. The results were
similar, and a closed aortic valve at 1 month was still
associated with fewer readmissions (HR: 0.68; 95% CI:
0.48 to 0.96; p  0.031). Preoperative variables signifi-
cantly associated with (fewer) readmissions in a multi-
variate model included residence within our hospital
extended referral zone of Minnesota and the neighboring
states (HR: 0.66; 95% CI: 0.48 to 0.91; p  0.011),
preoperative hemoglobin (HR: 0.91; 95% CI: 0.84 to
0.99; p  0.027) and preoperative NT-proBNP (HR:
0.98; 95% CI: 0.96 to 1.0 per 1,000-unit increase; p 
e after left ventricular assistive device implantation. Spline fit is depicted.n
with tim0.022); the C-statistic was 0.626.
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Readmissions to the hospital are of interest to the medical
community for multiple reasons. Primarily they reflect
patient morbidity and hence quality of life. They are also
important because of the cost incurred on the health care
system. In an era of increasing awareness of cost for health
Figure 3 Readmission Rate by Cause of Readmission Over Tim
The mean readmission rate during various time intervals after left ventricular assis
The mean number of readmissions and patients followed in each time interval are
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Figure 4 Comparison of Proportional Distributions of Causes fo
Left Ventricular Assist Device Based on Readmission
The proportional distribution of the grouped causes of readmission after left ventr
For each cause, the readmission rate is show in comparison with readmission durcare delivery, an appreciation of the readmission rate for a
particular medical condition is important for planning of
resource allocation. Among Medicare beneficiaries with an
implanted LVAD, 55.6% were readmitted within 6 months.
On average, these patients spent 29.8  45.0 days in the
ospital during the subsequent 2 years. These were consid-
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LVAD treatment (6).
We report an institutional readmission rate of 1.64 
1.97 with a cumulative incidence of 22% at 1 month and
Figure 5 Proportion of Patients With Defined Causes of Readm
The proportion of patients (for the entire group followed) with a defined cause of r
Major Primary Causes of Readmission After LVATable 3 Major Primary Causes of Readmiss
Cause
No. of
Readmissions
(BTT, DT)
Bleeding 66 (16, 50)
Gastrointestinal 51 (11, 40)
Other 15 (5, 10)
Cardiac 50 (11, 39)
Heart failure 21 (6, 15)
Arrhythmia 27 (5, 22)
Ventricular arrhythmia 24 (4, 20)
Chest pain 2
Infections 32 (9, 23)
Non–pump related 26 (7, 19)
Pump related 6 (2, 4)
Thrombosis 21 (9, 12)
Thromboembolic events 8 (3, 5)
Suspected LVAD thrombosis 13 (6, 7)
Major neurological events 13 (3, 10)
Cerebrovascular accident 6
Intracranial bleed 7 (2 trauma)
Biliary 8 (2, 6)
Pump events (abnormal
readouts, alarms)
7 (2,5)
Readmission causes were categorized based on mechanism (see Meth
total readmission (N  224) or patients (N  115). The number and
detailed. Other bleeding causes include identified bleeding including
Pump-related infections include drive-line infections as well as LVAD p
on the pathogenesis as either thrombotic (cerebrovascular accident) or bleed
Abbreviations as in Table 2.65% at 1 year after axial flow LVAD implantation. In the
HeartMate II clinical trial, a higher readmission rate of 2.64
events per patient-year is reported during a median
follow-up of 1.7 years; this was significantly reduced com-
ns After Left Ventricular Assist Device Implantation
sion as previously outlined is shown.
plantationfter LVAD Implantation
% (60 BTT,
164 DT)
Patients
(BTT, DT)
% (42 BTT,
73 DT)
29 (27, 30) 34 (8,26) 30 (19, 36)
27 (6, 21)
14 (5, 9)
22 (18, 24) 35 (7, 28) 30 (17, 38)
19 (4, 15)
19 (4, 15)
17 (3, 14)
2
14 (15, 14) 25 (8, 17) 22 (19, 23)
21 (6, 15)
5 (2, 3)
9 (15, 7) 16 (6, 10) 14 (14, 14)
7 (2, 5)
10 (5, 5)
6 (5, 6) 13 (3, 10) 11 (7, 14)
6
7
4 (3, 4) 6 (2, 4) 5 (5, 5)
3 (3, 3) 7 (2, 5) 6 (5, 7)
tion for more detail). Cumulative incidence was calculated by dividing
tion of readmissions in patients bridged to transplantation or DT are
anial bleed as well as anemia without an obvious bleeding source.
nfection. Major neurological events were primarily categorized basedissio
eadmisD Imion A
ods sec
propor
intracr
ocket iing. These were pooled together and are shown separately.
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is generally no longer used. The rate of readmissions that we
report after axial flow LVAD implantation is comparable to
reported rates after cardiac transplantation (7) and cardiac
surgery (8), to those after hospitalizations for heart failure
(9,10), or to those of general hospitalizations in a sick
population (11). Rates may be at first higher than reported
after a diagnosis of heart failure (0.87 readmissions per
patient-year) (12) but become comparable to these after the
initial 6-month postoperative period.
An important part of our analysis is related to the causes
of readmissions in patients supported by axial flow LVAD.
Understanding the causes may be important both from the
institutional standpoint (knowing why, when, and how
many patients get readmitted) as well as the patient per-
spective (what is the likelihood of being readmitted for a
specific reason). Using readmission cause as the case defi-
nition may be helpful in avoiding inconsistencies in report-
ing between centers. As an example, the incidence of
bleeding in axial flow LVAD patients was reported to range
between 5% and 81% (13). In this regard, a comparative
analysis of the different causes of readmissions may be useful
in directing future research because it may highlight areas of
greater importance to patient care.
In our analysis, the major causes for readmission were
bleeding, cardiac, infection, and thrombosis. Thus, our
findings were similar to the major late adverse events in the
HeartMate II clinical trial, which were bleeding, infection,
and arrhythmias. However, higher bleeding and higher
infection rates were previously reported. Cerebral throm-
botic events were noted mostly within the first 30 days (14).
Statistically Significant Univariate VariablesAssociated Readmissions After LVAD ImplantationTable 4 t tistically Significant Univaria e VariablesAssociated Readmissions After LVAD Implantation
Variable n HR 95% CI p Value
Residence in Minnesota or
neighboring state
115 0.63 0.48–0.84 0.002
Baseline hemoglobin, g% 115 0.90 0.84–0.96 0.003
Preoperative RIMP 80 0.34 0.16–0.71 0.004
Closed AV on 1-month
echocardiogram
113 0.64 0.48–0.88 0.006
Preoperative GFR, 10 ml/
min/1.73 m2
115 0.92 0.87–0.97 0.008
NT-proBNP at baseline,
(1,000 pg/ml)
88 0.98 0.96–0.99 0.022
Baseline LDH, 10 U/l 92 1.00 0.99–1.00 0.027
Baseline LA volume index,
ml/m2
95 0.99 0.98–1.00 0.032
Baseline RA/wedge
pressure ratio
103 1.81 1.05–3.13 0.032
Residence in Minnesota 115 0.75 0.57–0.98 0.033
Baseline ALT, log U/l 111 0.85 0.73–0.99 0.036
GFR preoperative to
baseline, 10 ml/min/
1.73 m2
115 0.93 0.87–1.00 0.039
Results of a univariate Anderson-Gill analysis for association with readmissions.
AV aortic valve; CI confidence interval; HR hazard ratio; other abbreviations as in Table 1.These differences may reflect our longer follow-up. In ouranalysis, the thrombotic event rate seems to increase during
the third year of follow-up. We also acknowledge that the
analysis reflects in part our clinical practice and patient
population, which may be different from those in the clinical
trial.
The causes of readmission in patients supported with an
LVAD is unique to this population. For comparison, after
hospitalization for heart failure in an elderly population, the
most common reasons for readmission were heart failure
(28%) and respiratory infections (6%). Gastrointestinal
bleeding and arrhythmias accounted for 2.5% each (10).
After cardiac transplantation, the primary reason for hospi-
talization was infection (51.5%) (7). In patients supported
by axial flow LVAD, bleeding complications are long
known to be a significant cause of morbidity (15), the reason
for which is unclear. Although the left ventricular output is
maintained by the LVAD, cardiac complications may be
caused by right ventricular dysfunction, arrhythmias, pump
malfunction, or aortic incompetence. Interestingly, aortic
regurgitation was not a frequent cause of readmissions,
perhaps due to our practice of treating any aortic regurgi-
tation during LVAD implantation. Pump-related infections
were infrequent in our cohort. Other infections were more
common; however, these are not specific to this patient
population and are a leading cause of readmissions after
surgery (8) or in heart failure (12). Thrombotic events,
including cerebrovascular events and pump thrombosis,
were among the leading causes of prolonged readmissions.
We observed a trend toward more readmissions for late
pump thrombosis with a decreased rate of bleeding compli-
cations during the third year of follow-up. It is possible that
this may be related to less stringent anticoagulation with
longer period of time post-implantation.
An interesting group of causes of readmissions is the
biliary events. These may be related to ongoing low-grade
hemolysis with increased bilirubin excretion. We now per-
form routine abdominal ultrasound before LVAD implan-
tation and consider elective cholecystectomy. Last, hospi-
talizations due to purely pump-related issues such as
technical difficulties, alarms, and abnormal readouts were
not common and occurred mostly during the second half of
the first year after implantation.
With the increasing growth of our LVAD program, we
have had an evolution in our practice in the care of the
LVAD recipient. We have taken a number of steps in the
clinical care and follow-up of these patients, acknowledging
their special needs. These now include enhancement of our
follow-up with regular protocol-driven follow-up visits to
the clinic and dedicated coordinator surveillance in between
visits. We implemented follow-up procedures such as right
heart catheterization, VO2 exercise, and 6-min walk tests.
Anticoagulation monitoring was enhanced, and early in-
volvement of subspecialists such as the infectious disease
and the gastrointestinal services is now a routine in our
practice.
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higher risk of readmission after implantation may be useful
in discharge and after-care planning. Although different
causes of readmission may have different and opposing
predictors, a comprehensive analysis may provide a general
assessment of patient well-being. However, any interpreta-
tion of the possible predictors in this paper must take into
account that the population selected consists of patients
who survived the operation to discharge. Interestingly,
living far from the implanting facility was associated with
more readmissions. This may be explained by a referral bias
because patients who are referred from a different location
are many times sicker than the local referrals. Decreased
hemoglobin at admission also emerged as being strongly
associated with readmissions and perhaps correlates with the
high incidence of readmissions for bleeding after implanta-
tion. Anemia was also a strong predictor of readmissions in
the heart failure population (12). Another observation was
that a higher admission pro–B-type natriuretic peptide level
was associated with fewer readmissions. Although this
appears counterintuitive, similar findings of lower rather
than higher levels of B-type natriuretic peptides were
associated with mortality in patients with end-stage heart
failure (16). This can be explained as a relative “exhaustion”
of the compensatory natriuretic peptide system at the
extremes of heart failure morbidity. Interestingly, we ob-
served that a closed aortic valve observed during echocardi-
ography at 1 month was associated with fewer readmissions.
This appears to be in contrast to the general belief that
maintaining at least partial opening of the valve by dialing
down the pump speed may benefit future morbidity. Al-
though longer follow-up may be needed, this observation
argues against the utility of the intermittent aortic valve
opening as a major determinant to guide the pump speed
setting.
In summary, this analysis shows our single-center expe-
rience of the occurrence and causes of hospital readmissions
over time after LVAD implantation. To the best of our
knowledge, this is the first analysis of this kind. We
demonstrate here for the first time that the rate decreases
over the first 6 months after implantation from 2.5 read-
missions per patient-year and then stabilizes at about 1 year.
Although the contribution of various causes of readmission
differed as a product of time after implantation, the 4
leading defined causes remained bleeding, cardiac, infection,
and thrombosis. Bleeding and cardiac causes are the leading
causes for the number of readmissions, and infection and
thrombosis were the leading causes for cumulative hospital
stay. Possible predictors of overall recurring admissions were
evaluated and may be helpful in trying to reduce readmis-
sion rates.
Study limitations. Our study has the obvious limitations of
a descriptive retrospective analysis and is not hypothesis
driven. Because many of the patients were followed else-
where before LVAD implantation, it is beyond the scope of
this paper to compare hospital admissions before and afterLVAD implantation. Being a single-centre study, it may
not be representative of what occurs at other centers.
Therefore, in interpreting the results, one should be con-
scious of the patient characteristics and management rou-
tines that we describe. Readmissions to other medical
facilities were not recorded. Although it is our policy to refer
patients with significant morbidity to be readmitted in our
facility, the overall number of readmissions may be under-
estimated. Another possible shortcoming of this referral bias
may be that patient readmissions included in the analysis
may be of a more severe nature and hence longer and more
complicated because shorter readmissions may have been
dealt with at a local facility.
Conclusions
Readmission rates to the implanting facility for recipients of
an axial flow LVAD are comparable to those previously
observed in stable community heart failure patients.
Rates are higher in the first 6 months after surgery.
Leading causes of readmission are bleeding, cardiac (heart
failure and arrhythmia), infection, and thrombosis. Associ-
ated variables such as admission hemoglobin and NT-
proBNP may help predict the general risk of readmissions.
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